One prominent example of a clinically approved PI3K inhibitor is BYL719 (alpelisib), which is given in combination with fulvestrant to patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring PIK3CA mutations [35] and is being evaluated for other indications in ongoing clinical trials. The gene discussed is PIK3CA; the disease is breast carcinoma.